Share:
Review

Surgery for Cutaneous Squamous Cell Carcinoma and its Limits in Advanced Disease

Author Affiliation(s)

Abstract

Surgery remains the first-line therapeutic option for most patients with cutaneous squamous cell carcinoma (cSCC). However, in the current therapeutic landscape, surgery must attempt to the complete tumor resection (R0 resection) with the lowest risk of surgical complications. This double aim is usually accomplished through standard excision with clinical margins in patients with low-risk tumors or by some of the micrographically controlled surgery procedures for patients with tumors at high-risk of local recurrence and metastasis. Surgery is also a first-line treatment for nodal metastases of cSCC as well as an option to consider in patients who develop recurrences while receiving immunotherapy, or as a palliation procedure in patients with advanced tumors. Neoadjuvant immunotherapy, that is the use of a medical treatment before surgery, is under investigation in patients with cSCC. The decision-making process and guidelines recommendations regarding cSCC surgery are reviewed in this manuscript.


 

Keywords : cutaneous squamous cell carcinoma, surgery, oncologic surgery, Mohs surgery, nodal surgery, nodal metastasis

References

1. Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, et al. Assessing physicians’ preferences on skin cancer treatment in Europe. Br J Dermatol. 2012;167 Suppl 2:29-35. DOI:10.1111/j.1365-2133.2012.11084.x. PMID: 22881585. 2. Work Group, Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578. DOI:10.1016/j.jaad.2017.10.007. PMID: 29331386. 3. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83-102. DOI:10.1016/j.ejca.2020.01.008. PMID: 32113942. 4. Squamous.pdf. Accessed August 10, 2021. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf 5. Chren M-M, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127(6):1351-1357. DOI:10.1038/sj.jid.5700740. PMID: 17301830. 6. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention - PubMed. Accessed August 10, 2021. https://pubmed.ncbi.nlm.nih.gov/32113941/ 7. Khan AA, Potter M, Cubitt JJ, et al. Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest. J Plast Reconstr Aesthet Surg. 2013;66(4):467-471. DOI:10.1016/j.bjps.2012.12.016. PMID: 23352886. 8. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies - PubMed. Accessed August 6, 2021. https://pubmed.ncbi.nlm.nih.gov/24191270/ 9. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery - PubMed. Accessed August 6, 2021. https://pubmed.ncbi.nlm.nih.gov/12160533/ 10. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241-248. DOI:10.1016/0190-9622(92)70178-i 11. Löser CR, Rompel R, Möhrle M, et al. S1 guideline: microscopically controlled surgery (MCS). J Dtsch Dermatol Ges. 2015;13(9):942-951. DOI:10.1111/ddg.12665. PMID: 26882393. 12. Mohs FE. Chemosurgical treatment of cancer of the skin; a microscopically controlled method of excision. Journal of the American Medical Association. 1948;138(8):564-569. DOI:10.1001/jama.1948.02900080022006. PMID: 18886775. 13. van Lee CB, Roorda BM, Wakkee M, et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2019;181(2):338-343. DOI:10.1111/bjd.17188. PMID: 30199574. 14. Stuart SE, Schoen P, Jin C, et al. Tumor recurrence of keratinocyte carcinomas judged appropriate for Mohs micrographic surgery using Appropriate Use Criteria. J Am Acad Dermatol. 2017;76(6):1131-1138.e1. DOI:10.1016/j.jaad.2016.12.045. PMID: 28365039. 15. Murray C, Sivajohanathan D, Hanna TP, et al. Patient Indications for Mohs Micrographic Surgery: A Systematic Review. J Cutan Med Surg. 2019;23(1):75-90. DOI:10.1177/1203475418786208. PMID: 30033747. 16. Moncrieff MD, Shah AK, Igali L, Garioch JJ. False-negative rate of intraoperative frozen section margin analysis for complex head and neck nonmelanoma skin cancer excisions. Clin Exp Dermatol. 2015;40(8):834-838. DOI:10.1111/ced.12743. PMID: 26290360. 17. Hutting KH, Bos PG, Kibbelaar RE, Veeger NJGM, Marck KW, Mouës CM. Effective excision of cutaneous squamous cell carcinoma of the face using analysis of intra-operative frozen sections from the whole specimen. J Surg Oncol. 2018;117(3):473-478. DOI:10.1002/jso.24870. PMID: 29073717. 18. Bovill ES, Banwell PE. Re-excision of incompletely excised cutaneous squamous cell carcinoma: histological findings influence prognosis. J Plast Reconstr Aesthet Surg. 2012;65(10):1390-1395. DOI:10.1016/j.bjps.2012.04.031. PMID: 22652292. 19. Spyropoulou G-A, Pavlidis L, Trakatelli M, et al. Cutaneous squamous cell carcinoma with incomplete margins demonstrate higher tumour grade on re-excision. J Eur Acad Dermatol Venereol. 2020;34(7):1478-1481. DOI:10.1111/jdv.16167. PMID: 31868990. 20. Genders RE, Marsidi N, Michi M, Henny EP, Goeman JJ, van Kester MS. Incomplete Excision of Cutaneous Squamous Cell Carcinoma; Systematic Review of the Literature. Acta Derm Venereol. 2020;100(6):adv00084. DOI:10.2340/00015555-3441. PMID: 32128598. 21. Forest V-I, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. 2010;116(5):1298-1304. DOI:10.1002/cncr.24855. PMID: 20052712. 22. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261. DOI:10.1016/j.jaad.2017.08.058. PMID: 29332705. 23. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma - PubMed. Accessed August 13, 2021. https://pubmed.ncbi.nlm.nih.gov/29701281/ 24. Lhote R, Lambert J, Lejeune J, et al. Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Series of 37 Cases and Systematic Review of the Literature. Acta Derm Venereol. 2018;98(7):671-676. DOI:10.2340/00015555-2942. PMID: 29648676. 25. Navarrete-Dechent C, Veness MJ, Droppelmann N, Uribe P. High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review. J Am Acad Dermatol. 2015;73(1):127-137. DOI:10.1016/j.jaad.2015.03.039. PMID: 26089049. 26. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150(1):19-24. DOI:10.1001/jamadermatol.2013.6675. PMID: 24226651. 27. Chang JM, Kosiorek HE, Dueck AC, et al. Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg. 2018;215(4):699-706. DOI:10.1016/j.amjsurg.2017.12.009. PMID: 29502857. 28. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302-311; discussion 311-313. DOI:10.1097/01.sla.0000181092.50141.fa. PMID: 16135917. 29. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature - PubMed. Accessed August 14, 2021. https://pubmed.ncbi.nlm.nih.gov/17083582/ 30. Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma - PubMed. Accessed August 14, 2021. https://pubmed.ncbi.nlm.nih.gov/24953417/ 31. Conway WC, Faries MB, Nicholl MB, et al. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16(6):1548-1552. DOI:10.1245/s10434-009-0420-x. PMID. 19277787. 32. Gurney B, Newlands C. Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma. Br J Oral Maxillofac Surg. 2014;52(4):294-300. DOI:10.1016/j.bjoms.2014.01.015. PMID: 24559975. 33. Radu S, Han D, Fowler G, Han G, Fortino J, Vetto JT. Relationship of patient age to tumor factors and outcomes among patients undergoing sentinel node biopsy for melanoma. Am J Surg. 2020;219(5):836-840. DOI:10.1016/j.amjsurg.2020.03.013. PMID: 32184009. 34. Jol J a. D, van Velthuysen MLF, Hilgers FJM, Keus RB, Neering H, Balm AJM. Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma. Eur J Surg Oncol. 2003;29(1):81-86. DOI:10.1053/ejso.2002.1330. PMID: 12559082. 35. Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015;37(12):1808-1815. DOI:10.1002/hed.23843. PMID: 24995842. 36. Smith JA, Virk S, Palme CE, et al. Age is not a predictor of prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2018;88(4):E273-E277. DOI:10.1111/ans.13757. PMID: 29611361. 37. Rodrigo JP, Grilli G, Shah JP, et al. Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: Systematic review. Eur J Surg Oncol. 2018;44(4):395-403. DOI:10.1016/j.ejso.2018.01.003. PMID: 29395434. 38. Wang JT, Palme CE, Wang AY, Morgan GJ, Gebski V, Veness MJ. In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome. J Laryngol Otol. 2013;127 Suppl 1:S2-7. DOI:10.1017/S0022215112002101. PMID: 23046820. 39. Knowing when not to operate. BMJ. 1999;318(7180):A. DOI: 10.1136/bmj.318.7180.0a. 40. Ferrarotto R, Amit M, Nagarajan P, et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. Published online June 29, 2021. DOI:10.1158/1078-0432.CCR-21-0585. PMID: 34187851.

Send mail to Author


Send Cancel